N. Penel, A. Adenis, and G. Bocci, Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?, Critical Reviews in Oncology/Hematology, vol.82, issue.1, pp.40-50, 2012.
DOI : 10.1016/j.critrevonc.2011.04.009

A. Adenis, I. Ray-coquard, A. Italiano, E. Chauzit, B. Bui-nguyen et al., A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours, British Journal of Cancer, vol.109, issue.10, pp.2574-2582, 2013.
DOI : 10.3109/10428194.2012.743657

N. Penel, S. Clisant, E. Dansin, C. Desauw, M. Dégardin et al., Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care, British Journal of Cancer, vol.14, issue.8, pp.1207-1219, 2010.
DOI : 10.1200/JCO.2005.01.8010

M. Jordan, R. Toso, D. Thrower, and L. Wilson, Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations., Proceedings of the National Academy of Sciences, vol.90, issue.20, pp.9552-9558, 1993.
DOI : 10.1073/pnas.90.20.9552

R. Foa, L. Norton, and A. Seidman, Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity, International Journal of Clinical & Laboratory Research, vol.33, issue.1, pp.6-14, 1994.
DOI : 10.1212/WNL.39.3.368

E. Rowinsky and R. Donehower, Paclitaxel (Taxol), New England Journal of Medicine, vol.332, issue.15, pp.1004-1018
DOI : 10.1056/NEJM199504133321507

A. Seidman, The emerging role of paclitaxel in breast cancer therapy, Clin Cancer Res, vol.1, pp.247-56, 1995.

E. Einsenhauer, T. Huinink, W. Swenerton, K. Gianni, L. Myles et al., European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion., Journal of Clinical Oncology, vol.12, issue.12, pp.2654-66, 1994.
DOI : 10.1200/JCO.1994.12.12.2654

M. Markman, J. Hall, D. Spitz, S. Weiner, L. Carson et al., Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer, Journal of Clinical Oncology, vol.20, issue.9, pp.2365-2374, 2002.
DOI : 10.1200/JCO.2002.09.130

W. Akerley, J. Herndon, M. Egorin, A. Lyss, H. Kindler et al., Weekly, high-dose paclitaxel in advanced lung carcinoma, Cancer, vol.346, issue.10, pp.2480-2486, 2003.
DOI : 10.1056/NEJMoa011954

W. Arai, Y. Hosoya, M. Hyodo, H. Haruta, K. Kurashina et al., Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1, International Journal of Clinical Oncology, vol.6, issue.Suppl 16, pp.146-155, 2007.
DOI : 10.1038/bjc.1995.114

O. Juan, A. Albert, J. Campos, V. Caranyana, J. Muñoz et al., Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel, Acta Oncologica, vol.20, issue.3, pp.367-75, 2007.
DOI : 10.1016/S1040-8428(00)00090-1

M. Ichikawa, R. Suzuki, K. Kataoka, Y. Noda, J. Shindoh et al., Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study, Lung Cancer, vol.69, issue.3, pp.319-341, 2010.
DOI : 10.1016/j.lungcan.2009.11.021

D. Rossi, D. Dennetta, M. Ugolini, P. Alessandroni, V. Catalano et al., Weekly Paclitaxel in Elderly Patients (Aged ??? 70 Years) with Advanced Non???Small-Cell Lung Cancer: An Alternative Choice? Results of a Phase II Study, Clinical Lung Cancer, vol.9, issue.5, pp.280-284, 2008.
DOI : 10.3816/CLC.2008.n.043

F. Joly, N. Houédé, S. Noal, C. Chevreau, F. Priou et al., Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study, Clinical Genitourinary Cancer, vol.7, issue.2, pp.28-33, 2009.
DOI : 10.3816/CGC.2009.n.018

N. Yamamoto, J. Tsurutani, N. Yoshimura, G. Asai, A. Moriyama et al., Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer, Anticancer Res, vol.26, pp.777-81, 2006.

C. Camps, C. Caballero, A. Blasco, M. Safont, A. Berrocal et al., Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability, Anticancer Res, vol.25, pp.4611-4615, 2005.

K. Yasuda, T. Igishi, Y. Kawasaki, K. Kato, S. Matsumoto et al., Phase II Study of Weekly Paclitaxel in Patients with Non-Small Cell Lung Cancer Who Have Failed Previous Treatments, Oncology, vol.66, issue.5, pp.347-52, 2004.
DOI : 10.1159/000079481

G. Ceresoli, V. Gregorc, S. Cordio, K. Bencardino, S. Schipani et al., Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer, Lung Cancer, vol.44, issue.2, pp.231-240, 2004.
DOI : 10.1016/j.lungcan.2003.11.006

G. Buccheri and D. Ferrigno, Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin, Lung Cancer, vol.45, issue.2, pp.227-263, 2004.
DOI : 10.1016/j.lungcan.2004.01.011

E. Esteban, L. González-de-sande, Y. Fernández, N. Corral, J. Fra et al., Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, Annals of Oncology, vol.14, issue.11, pp.1640-1647, 2003.
DOI : 10.1093/annonc/mdg456

M. Socinski, M. Schell, K. Bakri, A. Peterman, J. Lee et al., Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel, Cancer, vol.2, issue.6, pp.1265-73, 2002.
DOI : 10.3816/CLC.2000.n.026

URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.10835/pdf

P. Fidias, J. Supko, R. Martins, A. Boral, R. Carey et al., A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer, Clin Cancer Res, vol.7, pp.3942-3951, 2001.

M. Dipasquale, V. Murgia, A. Veccia, S. Brugnara, A. Caldara et al., Weekly paclitaxel after first-line failure in patients with advanced non-smallcell lung cancer: everyday clinical practice in a single Centre. Anti-Cancer Drugs, pp.654-663, 2017.

J. Park and J. Lee, Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum, Cancer Chemotherapy and Pharmacology, vol.28, issue.11, pp.247-54, 2015.
DOI : 10.1200/JCO.2009.25.4599

V. Petry, D. Gagliato, A. Leal, R. Arai, and E. Longo, Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2??? locally advanced breast cancer, Brazilian Journal of Medical and Biological Research, vol.9, issue.5, pp.479-85, 2015.
DOI : 10.2217/fon.12.196

G. Cancello, V. Bagnardi, C. Sangalli, E. Montagna, S. Dellapasqua et al., Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer, Clinical Breast Cancer, vol.15, issue.4, pp.259-65, 2015.
DOI : 10.1016/j.clbc.2015.03.002